ABSTRACT
AIM: Whole brain radiotherapy (WBRT) is commonly used to treat brain metastases (BM) from nonsmall cell lung cancer (NSCLC). Its utility is increasingly being questioned after a recent randomized trial (QUARTZ) showed that its omission did not significantly impact the survival or quality of life of their patients recruited from UK and Australian centers. We report the patient characteristics and survival outcomes of our local population in comparison with theirs. METHODS: Medical records of patients who received WBRT in two tertiary hospitals over 18 months were reviewed. Characteristics and survival outcomes of patient with NSCLC receiving WBRT for the first time were evaluated. Patients with prior excision of BM or stereotactic radiotherapy were excluded. Treatment details including radiotherapy dose and use of tyrosine kinase inhibitors (TKIs) were recorded. RESULTS: Between January 2015 and June 2016, 116 patients with NSCLC received WBRT for their BM. Their median age was 65 years (range, 36-85) and median follow-up duration was 110 days (range, 14-840). A total of 102 (88%) patients had their driver mutation tested of which 59 (58%) were epidermal growth factor receptor (EGFR) mutants. Factors predicting for better survival were female gender (P < .001), EGFR mutant receiving TKIs (P = .013), prescription other than 20 Gray in five fractions (P = .003), and presence of more than four BM (P = .001). CONCLUSION: Our patients appear to be considerably different from those recruited into the QUARTZ trial. Further prospective studies should be done to evaluate the value of WBRT in our population.
Subject(s)
Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Non-Small-Cell Lung/secondary , Cranial Irradiation , Lung Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Asia , Brain Neoplasms/mortality , Carcinoma, Non-Small-Cell Lung/mortality , Cranial Irradiation/methods , Cranial Irradiation/mortality , ErbB Receptors/genetics , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/radiotherapy , Male , Middle Aged , Mutation , Quality of LifeABSTRACT
PURPOSE: To determine the benefit of adding radiotherapy (RT) to chemotherapy for patients with locally advanced unresectable pancreatic cancer (LAUPC). METHODS: We searched MEDLINE for comparative studies comparing chemoradiotherapy with chemotherapy for patients with LAUPC. We performed the meta-analysis with random effects model. The primary outcome was overall survival (OS); secondary outcomes include progression-free survival (PFS) and adverse events (AE). RESULTS: We found five randomized (RCT) and three observational studies (OBS) including 830 patients. For RCTs, the addition of radiotherapy did not improve PFS (hazard ratio [HR] 0.90; 95% confidence interval [CI], 0.74-1.10; P = 0.30; I2 = 11%,) or OS (HR 0.87; 95% CI, 0.63-1.21; P = 0.41; I2 = 67%,) and was associated with increased grade 3 or 4 gastrointestinal AE. In contrast, OBS reported an improvement in PFS (HR 0.58; 95% CI, 0.37-0.92; P = 0.02; I2 = 32%) and OS (HR 0.48; 95% CI, 0.35-0.60; P < 0.0001; I2 = 6%). CONCLUSION: The addition of radiotherapy did not improve the OS and PFS in RCTs. The divergence in results seen in OBS may be due to imbalance in baseline characteristics. Further research incorporating biomarkers may help to better select patients who will benefit from RT.
